One of the most important things a patient can do is see a true MPN Specialist, the … Learn More
Treatments for ET and PV Moving Towards Disease Modification
by Christina T. Loguidice, OncLive Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera. Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia (ET) […]
Can Polycythemia Vera Patients Live a Normal Lifespan?
by David Wallace Transcript | Can Polycythemia Vera (PV) Patients Live a Normal Lifespan? David Wallace: So you had several important abstracts and one that our listeners with PV will be excited about. So tell us about the potential for normal life expectancy in PV. Dr. Abu-Zeinah: So this a project was inspired by our […]
What is Blood Cancer?
Someone around the world is diagnosed with blood cancer every 35 seconds (every 3 minutes in the U.S.)… but what does this mean? With over 137 different types of blood cancer and blood disorders, it can be difficult to understand what exactly is meant by the term ‘blood cancer.’ This video uses a medical approach […]
Impact of Anti-Endothelial Cell Antibodies in Patients with Polycythemia Vera and Thrombosis
Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested. A new analysis of anti-endothelial cell antibodies (AECAs) in patients with polycythemia vera (PV) suggests that autoimmunity may be one mechanism by which thrombosis develops. Abstract Polycythemia vera (PV) causes thrombosis. Erythrocytosis and cell adhesiveness are responsible for thrombosis. JAK2V617F causes inflammation […]
Lifestyle, Environmental and Host Factors in the development of MPN
Abstract Philadelphia-negative myeloproliferative neoplasms (MPNs) occur when there is over-production of myeloid cells stemming from hematopoietic stem cells with constitutive activation of JAK/STAT signaling, with JAK2V617F being the most commonly occurring somatic driver mutation. Chronic inflammation is a hallmark feature of MPNs and it is now evident that inflammation is not only a symptom of MPN but […]
- 1
- 2
- 3
- …
- 34
- Next Page »
